Palivizumab (Synagis®) – Prevention of Respiratory Syncytial Virus (RSV) in infants

Drug Name (Brand)	Palivizumab *(Synagis®)*
Indication	Prevention of Respiratory Syncytial Virus (RSV) in infants
Traffic Light Classification	Red
NICE TA (plus link)
Further Information: NICE recommendations, summary of meeting discussions, links to additional supporting docs etc. July 2011: The TAG noted that the recently updated section in Immunisations Against Infectious Disease (“The Green Book”), is now viewed as providing approved guidance in this condition. Clinicians should refer to http://www.dh.gov.uk/en/Publichealth/Immunisation/Greenbook/index.htm April 2013: NHS England SCG took over commissioning responsibility for this treatment.
Date of TAG recommendation / ratification		7/1/2011	Review Date	1/4/2027